Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06365307Not ApplicableRecruiting

Comparative Study of Gene-Activated Bone Substitute "Histograft" for Lumbar and Cervical Spinal Fusion

Role: lead

NCT04705857Unknown

Comparative Study of Gene-activated Bone Substitute and Autobone in Treatment of Long Bone Nonunions

Role: lead

NCT04511689Unknown

Comparative Study of Gene-activated Bone Substitute and Xenogenic Bone Matrix in Alveolar Ridge Augmentation

Role: lead

NCT03076138Not ApplicableCompleted

Gene-activated Bone Substitute for Maxillofacial Bone Regeneration

Role: lead

All 4 trials loaded